Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Denmark Revenue	-	2.75B	2.38B
Denmark Revenue Growth	-	15.58%	13.85%
United States Revenue	-	125.29M	56.28M
United States Revenue Growth	-	122.62%	-
Japan Revenue	-	116.82M	6.07M
Japan Revenue Growth	-	1823.76%	-
Revenue (Total)	22.31B	21.53B	-
Revenue (Total) Growth	3.62%	-	-

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
DARZALEX Royalties Revenue	2.17B	1.93B	1.67B
DARZALEX Royalties Revenue Growth	12.35%	15.91%	16.28%
Kesimpta Royalties Revenue	369.13M	308.65M	221.27M
Kesimpta Royalties Revenue Growth	19.60%	39.49%	97.30%
TEPEZZA Royalties Revenue	99.87M	102.37M	104.27M
TEPEZZA Royalties Revenue Growth	-2.45%	-1.82%	-9.02%
Other Product Royalties Revenue	80.75M	65.42M	35.84M
Other Product Royalties Revenue Growth	23.43%	82.53%	507.20%
Total Royalties Revenue	2.72B	2.41B	2.03B
Total Royalties Revenue Growth	12.95%	18.74%	21.73%
Reimbursement Revenue	95.31M	138.35M	127.97M
Reimbursement Revenue Growth	-31.11%	8.11%	8.66%
Milestone Revenue	104.26M	138.90M	174.32M
Milestone Revenue Growth	-24.94%	-20.32%	-31.48%
Collaboration Revenue	68.53M	60.15M	45.47M
Collaboration Revenue Growth	13.94%	32.28%	-4.87%
License Revenue	-	277.81K	-
Net Product Sales	313.38M	242.11M	62.35M
Net Product Sales Growth	29.43%	288.29%	-
Revenue (Other)	16.28B	16.13B	-
Revenue (Total)	22.31B	21.53B	-
Revenue (Total) Growth	3.62%	-	-

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
J&J Revenue	2.26B	2.00B	1.77B
J&J Revenue Growth	12.91%	13.20%	16.74%
Roche Revenue	101.42M	102.93M	104.27M
Roche Revenue Growth	-1.46%	-1.29%	-9.02%
Novartis Revenue	453.22M	391.99M	223.79M
Novartis Revenue Growth	15.62%	75.16%	90.73%
BioNTech Revenue	80.01M	120.71M	116.12M
BioNTech Revenue Growth	-33.72%	3.95%	13.92%
Pfizer Revenue	79.48M	74.04M	55.24M
Pfizer Revenue Growth	7.35%	34.02%	-7.09%
AbbVie Revenue	12.44M	54.73M	108.42M
AbbVie Revenue Growth	-77.26%	-49.52%	-35.86%
Other Collaboration Partner Revenue	2.28M	277.81K	-
Other Collaboration Partner Revenue Growth	719.92%	-	-
Revenue (Total)	22.31B	21.53B	-
Revenue (Total) Growth	3.62%	-	-

Updated Jun 30, 2025. Data Source: Fiscal.ai.